Alto Neuroscience (NYSE:ANRO) Trading 6.6% Higher – Time to Buy?

Alto Neuroscience, Inc. (NYSE:ANRO)’s share price rose 6.6% on Tuesday . The stock traded as high as $19.68 and last traded at $19.4420. Approximately 290,064 shares changed hands during trading, an increase of 2% from the average daily volume of 283,774 shares. The stock had previously closed at $18.24.

Analyst Ratings Changes

Several research firms recently weighed in on ANRO. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Alto Neuroscience in a research report on Wednesday, May 27th. BTIG Research raised their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Robert W. Baird cut their price objective on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Finally, Wedbush raised their target price on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $35.25.

Alto Neuroscience Trading Up 14.0%

The company has a market capitalization of $729.35 million, a PE ratio of -8.59 and a beta of 1.24. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. The stock has a fifty day moving average of $22.77 and a 200 day moving average of $19.36.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, sell-side analysts predict that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently made changes to their positions in ANRO. AQR Capital Management LLC purchased a new stake in Alto Neuroscience during the first quarter valued at approximately $52,000. Torren Management LLC bought a new position in Alto Neuroscience during the fourth quarter valued at $62,000. Invesco Ltd. purchased a new stake in shares of Alto Neuroscience in the first quarter valued at $67,000. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Alto Neuroscience by 13.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after purchasing an additional 2,055 shares during the period. Finally, Bridgeway Capital Management LLC raised its position in Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after purchasing an additional 25,000 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.